Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(510)
•••
Comment by 2b7f6fabon Aug 25, 2017 6:32pm
161 Views
Post# 26623713

RE:RE:RE:RE:RE:RE:Share count went from 125,231,526 to 126,481,526

RE:RE:RE:RE:RE:RE:Share count went from 125,231,526 to 126,481,526Why do you keep looking in the rear view mirror? Fully diluted there's 166 million share o/s. Divide $10 billion by 166 million. = $60.24/share.
bionicjoe wrote:
2b7f6fab wrote: I luv reality, convert the remaining warrants, exercise the options and TLT has about $18 million. Enuf to fund 10 more hurry up patients in an extended Ph1 bladder, good for breakthrough status, also fund Ph1 GBM, and extended Ph1 hurry up for breakthrough status also, and probably Ph1 lung cancer. TLT goes it alone and becomes the largest biotech stock in the universe.
bionicjoe wrote: Only on the TLT board will you find investors calling more dilution in the personal value of their investment good news.

Does anybody on this board subscribe to reality?......Anyone?




Correct me if I'm wrong but didn't 2017 start with 107,047,360 shares outstanding? If it's now up to 126,481,526 that would make it an 18% dilution in just 7 months. I've heard of creeping socialism but creeping dilution? Eighteen % off the sp valuation is 8 cents. And people wonder why the sp is having a hard time moving up? This company is awash in millions of overlapping cheap warrants and options. Every rally is quickly snuffed out by those investors anxious to sell. If the science is supposed to be so compelling then they should have done their PP's with 75 cent warrants. That would have ended this monkey business. Shareholders shouldn't be celebrating being manipulated. They should be pissed off.



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities